Abstract：
OBJECTIVE: To investigate effects of tirzepatide, a dual receptor agonist for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1), on eating behaviors.
METHODS: Eating behaviors were evaluated by using a validated questionnaire survey in 33 Japanese patients with type 2 diabetes mellitus (T2DM) (mean age: 51.8 years) who were treated with tirzepatide (2.5 mg/week for 4 weeks and then 5.0 mg/week) for 6 months (M).
RESULTS: Treatment with tirzepatide significantly decreased median hemoglobin A1c (HbA1c) (baseline/3 M/6 M: 7.3 %/6.0 %/5.8 %), mean body weight (BW) (baseline/3 M/6 M: 87.7 kg/82.0 kg/79.6 kg) and mean relative score of eating behaviors (baseline/3 M/6 M: 57.0/50.7/45.9). In the GLP-1 receptor agonist (GLP-1RA) naïve group (n = 20, men/women: 13/7), HbA1c and BW were continuously decreased up to 6 M. Changes in eating behaviors were mainly observed in the first 3 M. In the GLP-1RA non-naïve group (n = 13, men/women: 8/5), reductions in HbA1c and BW were predominant in the first 3 M, and changes in eating behaviors were observed up to 6 M. There were no significant correlations of changes in scores of eating behaviors with changes in glycemic control or those in BW.
CONCLUSIONS: Tirzepatide ameliorates eating behaviors as well as glycemic management and obesity in Japanese patients with T2DM, and the patterns of improvement are partially dependent on prior exposure to GLP-1RAs.
METHODS: Eating behaviors were evaluated by using a validated questionnaire survey in 33 Japanese patients with type 2 diabetes mellitus (T2DM) (mean age: 51.8 years) who were treated with tirzepatide (2.5 mg/week for 4 weeks and then 5.0 mg/week) for 6 months (M).
RESULTS: Treatment with tirzepatide significantly decreased median hemoglobin A1c (HbA1c) (baseline/3 M/6 M: 7.3 %/6.0 %/5.8 %), mean body weight (BW) (baseline/3 M/6 M: 87.7 kg/82.0 kg/79.6 kg) and mean relative score of eating behaviors (baseline/3 M/6 M: 57.0/50.7/45.9). In the GLP-1 receptor agonist (GLP-1RA) naïve group (n = 20, men/women: 13/7), HbA1c and BW were continuously decreased up to 6 M. Changes in eating behaviors were mainly observed in the first 3 M. In the GLP-1RA non-naïve group (n = 13, men/women: 8/5), reductions in HbA1c and BW were predominant in the first 3 M, and changes in eating behaviors were observed up to 6 M. There were no significant correlations of changes in scores of eating behaviors with changes in glycemic control or those in BW.
CONCLUSIONS: Tirzepatide ameliorates eating behaviors as well as glycemic management and obesity in Japanese patients with T2DM, and the patterns of improvement are partially dependent on prior exposure to GLP-1RAs.
摘要：
目的：为了研究替拉肽的作用，葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1（GLP-1）的双受体激动剂，关于饮食行为。
方法：对33名日本2型糖尿病（T2DM）患者（平均年龄：51.8岁）进行了问卷调查，对其饮食行为进行了评估，这些患者接受了替利西帕肽（2.5mg/周，4周，然后5.0mg/周）治疗6个月（M）。
结果：替瑞哌肽治疗可显著降低中位血红蛋白A1c（HbA1c）（基线/3M/6M：7.3％/6.0％/5.8％），平均体重（BW）（基线/3M/6M：87.7kg/82.0kg/79.6kg）和饮食行为的平均相对得分（基线/3M/6M：57.0/50.7/45.9）。在GLP-1受体激动剂（GLP-1RA）初始组（n=20，男性/女性：13/7），HbA1c和BW持续下降至6M。饮食行为的变化主要在前3M观察到。在GLP-1RA非初始组（n=13，男性/女性：8/5），HbA1c和BW的降低在前3M中占主导地位，观察到饮食行为的变化，直到6M。饮食行为得分的变化与血糖控制或BW的变化没有显着相关性。
结论：Tirzepatide改善了日本T2DM患者的饮食行为以及血糖管理和肥胖，和改善模式部分取决于之前的GLP-1RA暴露。
方法：对33名日本2型糖尿病（T2DM）患者（平均年龄：51.8岁）进行了问卷调查，对其饮食行为进行了评估，这些患者接受了替利西帕肽（2.5mg/周，4周，然后5.0mg/周）治疗6个月（M）。
结果：替瑞哌肽治疗可显著降低中位血红蛋白A1c（HbA1c）（基线/3M/6M：7.3％/6.0％/5.8％），平均体重（BW）（基线/3M/6M：87.7kg/82.0kg/79.6kg）和饮食行为的平均相对得分（基线/3M/6M：57.0/50.7/45.9）。在GLP-1受体激动剂（GLP-1RA）初始组（n=20，男性/女性：13/7），HbA1c和BW持续下降至6M。饮食行为的变化主要在前3M观察到。在GLP-1RA非初始组（n=13，男性/女性：8/5），HbA1c和BW的降低在前3M中占主导地位，观察到饮食行为的变化，直到6M。饮食行为得分的变化与血糖控制或BW的变化没有显着相关性。
结论：Tirzepatide改善了日本T2DM患者的饮食行为以及血糖管理和肥胖，和改善模式部分取决于之前的GLP-1RA暴露。
